PGA
CLVS

Premia Global Advisors’s Clovis Oncology, Inc. CLVS Stock Holding History

Premia Global Advisors’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-50
Closed -$2K – 168
2018
Q2 		$2K Hold
50
– – ﹤0.01% 171
2018
Q1 		$2K Buy
+50
New +$2.92K ﹤0.01% 368

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Premia Global Advisors's CLVS Position: Q3 2018 in Review

Premia Global Advisors sold out of Clovis Oncology, Inc. (CLVS) in Q3 2018, closing a stake of 50 shares — an estimated $2K sold.

Premia Global Advisors first reported a position in CLVS in Q1 2018 and held it in 2 quarters. The position peaked at $2K in Q2 2018. 192 funds tracked by Wall St. Rank hold CLVS as of Q3 2018.

  • Premia Global Advisors reported no remaining Clovis Oncology, Inc. position as of Q3 2018 after selling out during the quarter.
  • Premia Global Advisors sold 50 Clovis Oncology, Inc. shares in Q3 2018, an estimated $2K.
  • Premia Global Advisors first reported a position in Clovis Oncology, Inc. in Q1 2018 and held it in 2 quarters.
  • Premia Global Advisors's Clovis Oncology, Inc. position peaked at $2K in Q2 2018.
  • 192 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2018.

Based on Premia Global Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.